Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CHD2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CHD2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CHD2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CHD2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CHD2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CHD2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CHD2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CHD2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CHD2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006219730 | Thyroid | HT | cellular response to chemical stress | 54/1272 | 337/18723 | 3.07e-09 | 2.89e-07 | 54 |
GO:003459929 | Thyroid | HT | cellular response to oxidative stress | 46/1272 | 288/18723 | 4.97e-08 | 3.15e-06 | 46 |
GO:007048227 | Thyroid | HT | response to oxygen levels | 50/1272 | 347/18723 | 3.61e-07 | 1.65e-05 | 50 |
GO:003629327 | Thyroid | HT | response to decreased oxygen levels | 46/1272 | 322/18723 | 1.34e-06 | 5.14e-05 | 46 |
GO:000166627 | Thyroid | HT | response to hypoxia | 44/1272 | 307/18723 | 2.07e-06 | 7.53e-05 | 44 |
GO:00075178 | Thyroid | HT | muscle organ development | 44/1272 | 327/18723 | 1.09e-05 | 2.91e-04 | 44 |
GO:007145324 | Thyroid | HT | cellular response to oxygen levels | 26/1272 | 177/18723 | 1.62e-04 | 2.43e-03 | 26 |
GO:004346725 | Thyroid | HT | regulation of generation of precursor metabolites and energy | 20/1272 | 130/18723 | 4.83e-04 | 5.84e-03 | 20 |
GO:003629424 | Thyroid | HT | cellular response to decreased oxygen levels | 23/1272 | 161/18723 | 5.63e-04 | 6.62e-03 | 23 |
GO:007145618 | Thyroid | HT | cellular response to hypoxia | 21/1272 | 151/18723 | 1.36e-03 | 1.29e-02 | 21 |
GO:004886310 | Thyroid | HT | stem cell differentiation | 24/1272 | 206/18723 | 6.84e-03 | 4.19e-02 | 24 |
GO:0009060112 | Thyroid | PTC | aerobic respiration | 126/5968 | 189/18723 | 7.07e-23 | 1.78e-20 | 126 |
GO:0046034113 | Thyroid | PTC | ATP metabolic process | 167/5968 | 277/18723 | 1.18e-22 | 2.66e-20 | 167 |
GO:0006979113 | Thyroid | PTC | response to oxidative stress | 234/5968 | 446/18723 | 6.97e-20 | 9.77e-18 | 234 |
GO:0006091112 | Thyroid | PTC | generation of precursor metabolites and energy | 252/5968 | 490/18723 | 8.24e-20 | 1.13e-17 | 252 |
GO:0045333112 | Thyroid | PTC | cellular respiration | 140/5968 | 230/18723 | 9.60e-20 | 1.26e-17 | 140 |
GO:0006119113 | Thyroid | PTC | oxidative phosphorylation | 96/5968 | 141/18723 | 1.00e-18 | 1.15e-16 | 96 |
GO:0015980111 | Thyroid | PTC | energy derivation by oxidation of organic compounds | 176/5968 | 318/18723 | 2.67e-18 | 2.90e-16 | 176 |
GO:0062197113 | Thyroid | PTC | cellular response to chemical stress | 180/5968 | 337/18723 | 1.36e-16 | 1.16e-14 | 180 |
GO:0042773111 | Thyroid | PTC | ATP synthesis coupled electron transport | 69/5968 | 95/18723 | 3.82e-16 | 3.05e-14 | 69 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CHD2 | SNV | Missense_Mutation | novel | c.4091N>T | p.Ser1364Leu | p.S1364L | O14647 | protein_coding | tolerated(0.06) | benign(0.04) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
CHD2 | SNV | Missense_Mutation | novel | c.2893N>G | p.Lys965Glu | p.K965E | O14647 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
CHD2 | SNV | Missense_Mutation | rs769085842 | c.5329C>G | p.Leu1777Val | p.L1777V | O14647 | protein_coding | tolerated_low_confidence(0.11) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CHD2 | SNV | Missense_Mutation | novel | c.362G>A | p.Arg121Gln | p.R121Q | O14647 | protein_coding | deleterious(0.03) | probably_damaging(0.978) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHD2 | SNV | Missense_Mutation | novel | c.1696G>A | p.Gly566Ser | p.G566S | O14647 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHD2 | SNV | Missense_Mutation | | c.2855A>G | p.Glu952Gly | p.E952G | O14647 | protein_coding | tolerated(0.07) | benign(0.01) | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CHD2 | SNV | Missense_Mutation | novel | c.569N>A | p.Arg190His | p.R190H | O14647 | protein_coding | tolerated(0.06) | benign(0.026) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CHD2 | SNV | Missense_Mutation | novel | c.2125N>T | p.Leu709Phe | p.L709F | O14647 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
CHD2 | SNV | Missense_Mutation | rs748103788 | c.3752G>A | p.Arg1251His | p.R1251H | O14647 | protein_coding | tolerated(0.74) | benign(0.007) | TCGA-D8-A1JL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHD2 | SNV | Missense_Mutation | novel | c.5372N>T | p.Pro1791Leu | p.P1791L | O14647 | protein_coding | tolerated_low_confidence(0.23) | benign(0.003) | TCGA-LL-A441-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |